On episode #26 of the podcast “This Week in Virology”, Vincent, Alan, and Rich Condit converse about induction of polyomavirus replication in multiple sclerosis patients treated with the MS drug Tysabri, the extent of human polyomavirus infection, selection of influenza vaccines for the 2009-10 season, cowpox virus transmission from animals to humans, vaccinia-like virus infecting …
Biogen has announced that an anti-malaria compound may be useful for treating a brain infection, progressive multifocal leukoencephalopathy (PML), that is an adverse effect of the company’s multiple sclerosis/Crohn’s disease drug Tysabri. How does JC virus fit into this story? Tysabri is the trade name for Natalizumab, a monoclonal antibody against the cellular protein alpha-4 integrin. …
Polyomavirus JC, multiple sclerosis, Tysabri, and an anti-malaria drug Read More »
